Press release from the Extraordinary General Meeting in Vimian Group AB (publ) on 24 March 2023

Regulatory press release
Mar 24 2023

Press release from the Extraordinary General Meeting in Vimian Group AB (publ) on 24 March 2023

Vimian held its Extraordinary General Meeting today 24 March 2023. The Extraordinary General Meeting in Vimian resolved the following:

The Extraordinary General Meeting resolved, with the required majority, in accordance with the Board of Directors’ proposal, to carry out an issue of not more than 15,502,391 new ordinary shares, entailing an increase in the share capital of not more than SEK 25,852.660492, to partly finance the company’s acquisition of Viking Blues Pty Ltd. The right to subscribe for new shares shall only vest in Finn Pharmaceuticals Pty Limited as trustee for Finn Pharmaceuticals Trust, against payment by transfer of 36,519,732 shares in Viking Blues Pty Ltd.

The value of the contribution in kind as specified in the report by the Board of Directors pursuant to Chapter 13, Section 7 of the Swedish Companies Act corresponds to a subscription price of SEK 24.30 per share.

For further information about the resolution, refer to the minutes of the Extraordinary General Meeting, which will be available on the company’s website, www.vimian.com, no later than two weeks after the Extraordinary General Meeting.

About Vimian

Vimian is a global, fast-growing group of innovation-driven companies with a shared passion for making a positive impact through improving animal health. Together, we put science, technology and our customers’ needs at the centre of everything we do to deliver effective solutions to veterinary professionals, labs and pet parents around the world. We bring together pioneering and entrepreneurial businesses in animal health, with an aim to create a uniquely diversified proposition of products and services of the highest standard. Our group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to our networks, expertise, infrastructure and capital to accelerate innovation and growth. We are as passionate about supporting leadership within our existing businesses, as we are about welcoming new partners to the Vimian family – together helping us make an even greater impact by improving animal health. Headquartered in Stockholm, Sweden, Vimian and our family of companies reach over 15,000 customers in +90 markets, employ more than 900 people and have a combined annual turnover of approximately EUR 280 million. FNCA Sweden AB is appointed the Company’s Certified Adviser, info@fnca.se. For more information, please visit: www.vimian.com.